← Back to Patent Explorer
US4122186A Expired / Lapsed US ⏱️ 0.0 years remaining

Acetohydroxamic acids

Assignee: Cephalon France SAS
•
Filing: 1977-03-17
•
Granted: 1978-10-24
•
Expires: 1997-03-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention provides new acetohydroxamic acid derivatives, having interesting properties on the central nervous system, of the formula: R1R2R3C-CO-NHOH, in which R2 and R3 are each hydrogen or C1-6 alkyl, and R1 is C1-6 alkyl Z1Z2 N (where Z1 and Z2 are each phenyl, substituted phenyl, or cycloalkyl), substituted hydantoinyl, benzhydroxylcarboxamido, Z3CH2- (where Z3 = optionally substituted aryl), Z4-A- (where Z4 is optionally substituted phenyl or naphthyl, and A is -NH-, -N(C1-4 alkyl)-, -N(C5-6 cycloalkyl)-, -NHCO-, -N(C1-4 alkyl)CO-, -N(C5-6 cycloalkyl)CO-, -CONH-, -CON(C1-4 alkyl)-, -CON(C5-6 cycloalkyl)-, -NHCONH-, -N(C5H6)CONH-, or -N(substituted phenyl)CONH-, optionally substituted benzimidazolyl, or an optionally substituted tricyclic radical, and their metal and acid addition salts.

Inventors

  • 👤 Louis Lafon

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 09:53
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/14; C07D295/145; C07D295/15; A; A61; A61P; A61P25/00; A61P25/08; C07C; C07C275/00; C07C275/28; C07C275/30; C07C323/00; C07C57/00; C07C57/64; C07C57/72; C07D223/00; C07D223/14; C07D223/18; C07D223/22; C07D233/00; C07D233/54; C07D233/66; C07D233/72; C07D233/74; C07D233/76; C07D235/00; C07D235/02; C07D235/04; C07D235/06; C07D235/16; C07D279/00; C07D279/10; C07D279/14; C07D279/18; C07D279/22; C07D317/00; C07D317/08; C07D317/44; C07D317/46; C07D317/48; C07D317/50; C07D317/56

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 110 words
An acetohydroxamic acid of the formula: ##STR80## (in which R 2 and R 3 , which may be identical or different, each represent the hydrogen atom or a C 1 -C 6 alkyl group, Z 1 and Z 2 , which may be identical or different, each represent a C 5 -C 6 cycloalkyl group, a phenyl group or a phenyl group substituted by one or more C 1 -C 4 -alkyl groups, C 1 -C 4 -alkoxy groups, halogen, CF 3 , NO 2 or NH 2 groups), its metal salts and acid addition salts when one or both of Z 1 and Z 2 contains a basic group.
Claim 2
Dependent Claim 110 words
An acetohydroxamic acid of the formula: ##STR80## (in which R 2 and R 3 , which may be identical or different, each represent the hydrogen atom or a C 1 -C 6 alkyl group, Z 1 and Z 2 , which may be identical or different, each represent a C 5 -C 6 cycloalkyl group, a phenyl group or a phenyl group substituted by one or more C 1 -C 4 -alkyl groups, C 1 -C 4 -alkoxy groups, halogen, CF 3 , NO 2 or NH 2 groups), its metal salts and acid addition salts when one or both of Z 1 and Z 2 contains a basic group.
Claim 3
Dependent Claim 35 words
A compound according to claim 1, in which Z 1 = Z 2 = cyclohexyl, phenyl or halogenophenyl, R 2 = H, CH 3 or C 2 H 5 , and R 3 = H.
Claim 4
Dependent Claim 6 words
N,N-Diphenylcarbamoyl-acetohydroxamic acid and its metal salts.
Claim 5
Dependent Claim 6 words
N,N-Diphenylcarbamoyl-acetohydroxamic acid and its metal salts.
Claim 6
Dependent Claim 6 words
2-(N,N-Diphenylcarbamoyl)-propionohydroxamic acid and its metal salts.
Claim 7
Dependent Claim 6 words
2-(N,N-Diphenylcarbamoyl)-propionohydroxamic acid and its metal salts.
Claim 8
Dependent Claim 6 words
2-(N,N-Diphenylcarbamoyl)-butyrohydroxamic acid and its metal salts.
Claim 9
Dependent Claim 6 words
2-(N,N-Diphenylcarbamoyl)-butyrohydroxamic acid and its metal salts.
Claim 10
Dependent Claim 6 words
N,N-Dicyclohexylcarbamoyl-acetohydroxamic acid and its metal salts.
Claim 11
Dependent Claim 6 words
N,N-Dicyclohexylcarbamoyl-acetohydroxamic acid and its metal salts.
Claim 12
Dependent Claim 31 words
A pharmaceutical composition, comprising, in association with a pharmaceutically acceptable excipient, at least one compound according to claim 1, or one of its non-toxic metal salts or addition salts with acids.

References Cited (Backward Citations)

GB894119A Cited
US3728380A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1981-10-23 1982-04-24 1982-10-24 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1985-10-23 1986-04-24 1986-10-24 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1989-10-23 1990-04-24 1990-10-24 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag